AJP - GI AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 294: G9-G12, 2008. First published November 1, 2007; doi:10.1152/ajpgi.00467.2007
0193-1857/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/1/G9    most recent
00467.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mallat, A.
Right arrow Articles by Lotersztajn, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallat, A.
Right arrow Articles by Lotersztajn, S.

THEMES

Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver

A. Mallat and S. Lotersztajn

INSERM, U841; Université Paris 12-Val de Marne; AP-HP, Groupe Henri Mondor-Albert Chenevier, Service d'Hépatologie et de Gastroentérologie, Créteil, France

Submitted 10 October 2007 ; accepted in final form 29 October 2007

Cannabinoid receptors (CB1 and CB2) and their endogenous ligands (endocannabinoids) have recently emerged as novel mediators of liver diseases. Endogenous activation of CB1 receptors promotes nonalcoholic fatty liver disease (NAFLD) and progression of liver fibrosis associated with chronic liver injury; in addition, CB1 receptors contribute to the pathogenesis of portal hypertension and cirrhotic cardiomyopathy. CB2 receptor-dependent effects are also increasingly characterized, including antifibrogenic effects and regulation of liver inflammation during ischemia-reperfusion and NAFLD. It is likely that the next few years will allow us to delineate whether molecules targeting CB1 and CB2 receptors are useful therapeutic agents for the treatment of chronic liver diseases.

cannabinoid receptors


Address for reprint requests and other correspondence: S. Lotersztajn, INSERM, U 841, Institut Mondor de recherche Biomédicale Hôpital Henri Mondor 94010 Créteil, France (e-mail: Sophie.Lotersztajn{at}creteil.inserm.fr)




This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Duncan, A. Mouihate, K. Mackie, C. M. Keenan, N. E. Buckley, J. S. Davison, K. D. Patel, Q. J. Pittman, and K. A. Sharkey
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats
Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G78 - G87.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
V. L. Hegde, S. Hegde, B. F. Cravatt, L. J. Hofseth, M. Nagarkatti, and P. S. Nagarkatti
Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells
Mol. Pharmacol., July 1, 2008; 74(1): 20 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
P. Pacher and B. Gao
Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases
Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G850 - G854.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.